274 related articles for article (PubMed ID: 28065619)
1. Tumor-associated macrophage expression of PD-L1 in implants of high grade serous ovarian carcinoma: A comparison of matched primary and metastatic tumors.
Gottlieb CE; Mills AM; Cross JV; Ring KL
Gynecol Oncol; 2017 Mar; 144(3):607-612. PubMed ID: 28065619
[TBL] [Abstract][Full Text] [Related]
2. PD-L1 expression is associated with tumor-infiltrating T cells and favorable prognosis in high-grade serous ovarian cancer.
Webb JR; Milne K; Kroeger DR; Nelson BH
Gynecol Oncol; 2016 May; 141(2):293-302. PubMed ID: 26972336
[TBL] [Abstract][Full Text] [Related]
3. Association and prognostic significance of BRCA1/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1/PD-L1 in high grade serous ovarian cancer.
Strickland KC; Howitt BE; Shukla SA; Rodig S; Ritterhouse LL; Liu JF; Garber JE; Chowdhury D; Wu CJ; D'Andrea AD; Matulonis UA; Konstantinopoulos PA
Oncotarget; 2016 Mar; 7(12):13587-98. PubMed ID: 26871470
[TBL] [Abstract][Full Text] [Related]
4. The immune suppressive factors CD155 and PD-L1 show contrasting expression patterns and immune correlates in ovarian and other cancers.
Smazynski J; Hamilton PT; Thornton S; Milne K; Wouters MCA; Webb JR; Nelson BH
Gynecol Oncol; 2020 Jul; 158(1):167-177. PubMed ID: 32446718
[TBL] [Abstract][Full Text] [Related]
5. Expression of programmed cell death ligand 1 and immune checkpoint markers in residual tumors after neoadjuvant chemotherapy for advanced high-grade serous ovarian cancer.
Kim HS; Kim JY; Lee YJ; Kim SH; Lee JY; Nam EJ; Kim S; Kim SW; Kim YT
Gynecol Oncol; 2018 Dec; 151(3):414-421. PubMed ID: 30314669
[TBL] [Abstract][Full Text] [Related]
6. Ovarian low and high grade serous carcinomas: hidden divergent features in the tumor microenvironment.
Ciucci A; Zannoni GF; Buttarelli M; Martinelli E; Mascilini F; Petrillo M; Ferrandina G; Scambia G; Gallo D
Oncotarget; 2016 Oct; 7(42):68033-68043. PubMed ID: 27462782
[TBL] [Abstract][Full Text] [Related]
7. PD-L1 Expression and Intratumoral Heterogeneity Across Breast Cancer Subtypes and Stages: An Assessment of 245 Primary and 40 Metastatic Tumors.
Dill EA; Gru AA; Atkins KA; Friedman LA; Moore ME; Bullock TN; Cross JV; Dillon PM; Mills AM
Am J Surg Pathol; 2017 Mar; 41(3):334-342. PubMed ID: 28195880
[TBL] [Abstract][Full Text] [Related]
8. Application of Immunoprofiling Using Multiplexed Immunofluorescence Staining Identifies the Prognosis of Patients with High-Grade Serous Ovarian Cancer.
Lee SW; Lee HY; Kang SW; Kim MJ; Lee YJ; Sung CO; Kim YM
Int J Mol Sci; 2021 Sep; 22(17):. PubMed ID: 34502561
[TBL] [Abstract][Full Text] [Related]
9. The Prognostic Significance of Tumor-Infiltrating Lymphocytes, PD-L1, BRCA Mutation Status and Tumor Mutational Burden in Early-Stage High-Grade Serous Ovarian Carcinoma-A Study by the Spanish Group for Ovarian Cancer Research (GEICO).
Pizarro D; Romero I; Pérez-Mies B; Redondo A; Caniego-Casas T; Carretero-Barrio I; Cristóbal E; Gutiérrez-Pecharromán A; Santaballa A; D'Angelo E; Hardisson D; Vieites B; Matías-Guiu X; Estévez P; Guerra E; Prat J; Poveda A; López-Guerrero JA; Palacios J
Int J Mol Sci; 2023 Jul; 24(13):. PubMed ID: 37446361
[TBL] [Abstract][Full Text] [Related]
10. [Expression and significance of PD-1 and PD-L1 in the specimens of epithelial ovarian cancer].
Ju C; Gao JC; Zhang PX; Zhang KN; Yang S; Kang TJ; Zhao HZ; Qi WJ; Zhang QP; Kong FD; Guan HW; Shi H
Zhonghua Fu Chan Ke Za Zhi; 2020 Aug; 55(8):529-534. PubMed ID: 32854477
[No Abstract] [Full Text] [Related]
11. Tumor genomic, transcriptomic, and immune profiling characterizes differential response to first-line platinum chemotherapy in high grade serous ovarian cancer.
Weberpals JI; Pugh TJ; Marco-Casanova P; Goss GD; Andrews Wright N; Rath P; Torchia J; Fortuna A; Jones GN; Roudier MP; Bernard L; Lo B; Torti D; Leon A; Marsh K; Hodgson D; Duciaume M; Howat WJ; Lukashchuk N; Lazic SE; Whelan D; Sekhon HS
Cancer Med; 2021 May; 10(9):3045-3058. PubMed ID: 33811746
[TBL] [Abstract][Full Text] [Related]
12. Targetable Immune Regulatory Molecule Expression in High-Grade Serous Ovarian Carcinomas in African American Women: A Study of PD-L1 and IDO in 112 Cases From the African American Cancer Epidemiology Study (AACES).
Mills AM; Peres LC; Meiss A; Ring KL; Modesitt SC; Abbott SE; Alberg AJ; Bandera EV; Barnholtz-Sloan J; Bondy ML; Cote ML; Funkhouser E; Moorman PG; Peters ES; Schwartz AG; Terry PD; Wallace K; Schildkraut JM
Int J Gynecol Pathol; 2019 Mar; 38(2):157-170. PubMed ID: 29485423
[TBL] [Abstract][Full Text] [Related]
13. Biomarkers expression among paired serous ovarian cancer primary lesions and their peritoneal cavity metastases in treatment-naïve patients: A single-center study.
Nikas IP; Lee C; Song MJ; Kim B; Ryu HS
Cancer Med; 2022 Jun; 11(11):2193-2203. PubMed ID: 35212471
[TBL] [Abstract][Full Text] [Related]
14. Prognostic value of tumor PD-L1 expression combined with CD8
Wang Q; Lou W; Di W; Wu X
Int Immunopharmacol; 2017 Nov; 52():7-14. PubMed ID: 28846888
[TBL] [Abstract][Full Text] [Related]
15. Tumor-associated macrophages and the tumor immune microenvironment of primary and recurrent epithelial ovarian cancer.
Ojalvo LS; Thompson ED; Wang TL; Meeker AK; Shih IM; Fader AN; Cimino-Mathews A; Emens LA
Hum Pathol; 2018 Apr; 74():135-147. PubMed ID: 29288043
[TBL] [Abstract][Full Text] [Related]
16. Cancer-associated stroma significantly contributes to the mesenchymal subtype signature of serous ovarian cancer.
Zhang Q; Wang C; Cliby WA
Gynecol Oncol; 2019 Feb; 152(2):368-374. PubMed ID: 30448260
[TBL] [Abstract][Full Text] [Related]
17. Multiple direct and indirect mechanisms drive estrogen-induced tumor growth in high grade serous ovarian cancers.
Ciucci A; Zannoni GF; Buttarelli M; Lisi L; Travaglia D; Martinelli E; Scambia G; Gallo D
Oncotarget; 2016 Feb; 7(7):8155-71. PubMed ID: 26797759
[TBL] [Abstract][Full Text] [Related]
18. The increase of circulating PD-L1-expressing CD68(+) macrophage in ovarian cancer.
Qu QX; Huang Q; Shen Y; Zhu YB; Zhang XG
Tumour Biol; 2016 Apr; 37(4):5031-7. PubMed ID: 26541760
[TBL] [Abstract][Full Text] [Related]
19. Membranous and Cytoplasmic Expression of PD-L1 in Ovarian Cancer Cells.
Qu QX; Xie F; Huang Q; Zhang XG
Cell Physiol Biochem; 2017; 43(5):1893-1906. PubMed ID: 29055949
[TBL] [Abstract][Full Text] [Related]
20. A Complex Network of Tumor Microenvironment in Human High-Grade Serous Ovarian Cancer.
Kreuzinger C; Geroldinger A; Smeets D; Braicu EI; Sehouli J; Koller J; Wolf A; Darb-Esfahani S; Joehrens K; Vergote I; Vanderstichele A; Boeckx B; Lambrechts D; Gabra H; Wisman GBA; Trillsch F; Heinze G; Horvat R; Polterauer S; Berns E; Theillet C; Cacsire Castillo-Tong D
Clin Cancer Res; 2017 Dec; 23(24):7621-7632. PubMed ID: 28972047
[No Abstract] [Full Text] [Related]
[Next] [New Search]
